

Acute Myeloid Leukemia with NUP98::LNP1 Fusion Mimicking Chronic Myeloid Leukemia

Haiyang Wang^{1*}, Yu Peng^{2*}, Zailin Yang²

¹The Affiliated Hospital of Xuzhou Medical University, Department of Hematology, Xuzhou, China

²Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Department of Hematology-Oncology, Chongqing, China

* These authors' contribution is equally to this work.

Zailin Yang, M.D., Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Department of Hematology-Oncology, Chongqing, China
zailinyang@cqu.edu.cn

October 14, 2024

March 17, 2025

A 60-year-old female patient presented with a history of hepatitis, tuberculosis and gastric cancer, developed recurrent fever during the treatment for gastric cancer. Peripheral blood (PB) examination showed white blood cell count of $47.7 \times 10^9/L$, consisting 1% blasts, 1% promyelocytes, 2% neutrophilic myelocyte, 5% neutrophilic metamyelocytes, 13% neutrophils, 8% lymphocytes, 3% monocytes, 3% eosinophils, and 64% basophils. The hemoglobin concentration of 87 g/L, and platelet count of $75 \times 10^9/L$. The bone marrow (BM) smear displayed an active proliferation of granulocytes, with 10% myeloblasts (Figure A). The proportion of eosinophils and basophils in the BM was also notably increased, accounting for 9% and 24%, respectively (Figure A). Additionally, the percentage of basophils in the PB was significantly elevated, reaching 52% (Figure B). The morphologic features of BM and PB closely mimic the chronic myeloid leukemia (CML) in chronic high-risk phase, characterized by a significant elevation in basophils. Interestingly, both RT-qPCR and FISH indicated negativity for the *BCR::ABL1* fusion gene. The chromosomal karyotype was $46,XX,t(3;11)(q12.2;p15.4)$. Meanwhile, RNA sequencing identified only the *NUP98::LNP1* fusion transcript in this case, with no detectable mutations in other genes (e.g., *ASXL1*, *SETBP1*, *NRAS*, *KRAS*, *SRSF2*, *TET2*, *CBL*, *CSF3R*, *JAK2*, *ETNK1*, *SETBP1*, etc.). Ultimately, a diagnosis of acute myeloid leukemia with *NUP98* rearrangement was established, as AML with *NUP98* rearrangements is exempt from the historical threshold of 20% blasts according to WHO 2022 guidelines^[1,2].

AML with *NUP98::LNPI* fusion transcripts are extremely rare. To date, only one case has been reported in which the blasts count exceeded 20%^[3]. This case represents the first reported instance of specific morphologic presentation in AML with *NUP98::LNPI* fusion transcripts. Additionally, numerous studies have demonstrated that *NUP98* rearrangements are associated with an unfavorable prognosis, highlighting the critical importance of their identification^[4-6].

AUTHOR CONTRIBUTIONS

Z.Y and H.W wrote the manuscript, Y.P collect the data and information of patient. All authors reviewed and approved the final manuscript.

DATA AVAILABILITY STATEMENT

The data of this article are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

CONFLICT OF INTEREST DISCLOSURE

The authors declare no conflict of interest.

ETHICS APPROVAL STATEMENT

This study protocol was reviewed and approved by Chongqing University Cancer Hospital.

PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES

N/A.

CLINICAL TRIAL REGISTRATION

N/A.

References:

1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022;36:1703-1719.
2. The WHO Classification of Tumours Editorial Board. WHO classification of Tumours: Haematolymphoid Tumours (5th edition)[M] . Lyon, France. IARC Press, 2024.
3. Gorello P, Brandimarte L, La Starza R, Pierini V, Bury L, Rosati R, et al. T(3;11)(q12;p15)/NUP98-LOC348801 fusion transcript in acute myeloid leukemia. *Haematologica*. 2008;93:1398-1401.
4. Heikamp EB, Henrich JA, Perner F, Wong EM, Hatton C, Wen Y, et al. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. *Blood*. 2022;139:894-906.
5. Tian J, Zhu Y, Li J, Yang G, Weng X, Huang T, et al. The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients. *Blood Cancer J*. 2024;14:81.
6. Michmerhuizen NL, Klco JM, Mullighan CG. Mechanistic insights and potential therapeutic approaches for NUP98-rearranged hematologic malignancies. *Blood*. 2020;136:2275-2289.





Figure A and B, $\times 1000$ original magnification, Wright–Giemsa stain. The red arrow points to a myeloblast, the black arrow points to an eosinophil, and the green arrow points to a basophils.